Evonik: Corporate Strategic Intelligence

September 10, 2018 | Research Report

This report offers a breakdown of Evonik’s offerings, its approach to innovation, and its place in the market. The report is part of a Lux series focused on major chemical and materials industry players. Evonik was created in 2007 as a fusion of two German industrial giants, the coal company RAG and the chemical company Degussa. Evonik was formed specifically to pay for remediation of environmental damage stemming from RAG’s coal mining. By 2016, Evonik had shed unrelated businesses to become strictly a chemical company. It is now further distilling its portfolio to become a more focused specialty chemicals player. The firm invests significantly in R&D, which, along with its strong external innovation focus through its CVC group, demonstrates its commitment to tech innovation. R&D is mostly focused on “four growth engines”: health and care, smart materials, animal nutrition, and specialty additives. Through its Creavis R&D organization, some 10% of its R&D efforts are focused on mid- and long-term projects.


  • Chemicals
  • CPG
  • Government & Non-Profit

Table of Contents

  • Title page

Lead Analyst

Research Associate


Matthew Wagner, Ph.D.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978